0000899243-19-026793.txt : 20191106 0000899243-19-026793.hdr.sgml : 20191106 20191106172314 ACCESSION NUMBER: 0000899243-19-026793 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20191106 FILED AS OF DATE: 20191106 DATE AS OF CHANGE: 20191106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Novartis Bioventures Ltd CENTRAL INDEX KEY: 0001297709 STATE OF INCORPORATION: D0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39114 FILM NUMBER: 191197328 BUSINESS ADDRESS: STREET 1: C/O NOVARTIS INTERNATIONAL AG STREET 2: WSJ-200.220 CITY: CH-4002 BASEL STATE: V8 ZIP: 0000000000 BUSINESS PHONE: 41-61-324-6210 MAIL ADDRESS: STREET 1: C/O NOVARTIS INTERNATIONAL AG STREET 2: WSJ-200.220 CITY: CH-4002 BASEL STATE: V8 ZIP: 0000000000 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: NOVARTIS AG CENTRAL INDEX KEY: 0001114448 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39114 FILM NUMBER: 191197329 BUSINESS ADDRESS: STREET 1: LICHTSTRASSE 35 CITY: BASEL STATE: V8 ZIP: CH 4056 BUSINESS PHONE: 01141613241111 MAIL ADDRESS: STREET 1: LICHTSTRASSE 35 CITY: BASEL STATE: V8 ZIP: CH 4056 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Galera Therapeutics, Inc. CENTRAL INDEX KEY: 0001563577 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461454898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 LINDENWOOD DRIVE STREET 2: SUITE 405 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 610-725-1500 MAIL ADDRESS: STREET 1: 101 LINDENWOOD DRIVE STREET 2: SUITE 405 CITY: MALVERN STATE: PA ZIP: 19355 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2019-11-06 0 0001563577 Galera Therapeutics, Inc. GRTX 0001297709 Novartis Bioventures Ltd C/O NOVARTIS VENTURE FUND FORUM 1 - 1.32, LICHTSTRASSE 35 BASEL V8 CH-4056 SWITZERLAND 0 0 1 0 0001114448 NOVARTIS AG LICHTSTRASSE 35 BASEL V8 CH-4056 SWITZERLAND 0 0 1 0 Series A Preferred Stock Common Stock 1779864 I See footnote Series B Preferred Stock Common Stock 1423891 I See footnote Series C Preferred Stock Common Stock 89311 I See footnote Novartis Bioventures Ltd. Is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities. Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock on a 0.197763-for-one basis at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. Exhibit 24 - Power of Attorney Novartis Bioventures Ltd., By: /s/ Bart Dzikowski, Name: Bart Dzikowski, Title: Secretary of the Board, By: /s/ Stephan Sandmeier, Name: Stephan Sandmeier, Title: Authorized Signatory 2019-11-06 Novartis AG, By: /s/ Bart Dzikowski, Name: Bart Dzikowski, Title: Attorney-in-Fact, By: /s/ Stephan Sandmeier, Name: Stephan Sandmeier, Title: Attorney-in-Fact 2019-11-06 EX-24 2 attachment1.htm EX-24 DOCUMENT

                                   EXHIBIT 24

                               POWER OF ATTORNEY


     We, the undersigned, under the authority granted to each of us to sign
jointly on behalf of Novartis AG, hereby grant powers to Bart Dzikowski, Anja
Koenig, Stephan Sandmeier, Florian Muellershausen, Beat Steffen, Marc Ceulemans
and Florent Gros and constitute and appoint any two of them jointly as our true
and lawful attorneys and representatives and to act on our behalf and to sign
filings to be made with the U.S. Securities and Exchange Commission (the "SEC")
relating to the shares of Galera Therapeutics, Inc. (the "Company") held by
Novartis Bioventures Ltd., an indirect subsidiary of Novartis AG, as required by
the SEC (the "SEC Filings"), and to undertake and carry out all tasks and
formalities on our behalf which may be required in connection with giving effect
to the SEC Filings.

We, the undersigned, undertake to ratify and confirm whatever our true and
lawful attorneys do or purport to do in good faith in the exercise of any power
conferred by this Power of Attorney.

We, the undersigned, declare that a person who deals with our true and lawful
attorneys in good faith may accept a written statement signed by such attorneys
to the effect that this Power of Attorney has not been revoked as
conclusive evidence of that fact.

The authority granted by this Power of Attorney shall expire immediately  after
the SEC Filings are no longer required.

IN WITNESS WHEREOF, this Power of Attorney is duly signed on this  21 day of
February 2019.


                                                    Novartis AG

                                                   /s/ K. Roth Pellanda
                                                   Name: Katja Roth Pellanda
                                                   Title: Authorized Signatory


                                                   /s/ C. Rehm
                                                   Name: Christian Rehm
                                                   Title: Authorized Signatory